Global Market's Estimated Value Stocks For October 2026
As global markets navigate a landscape marked by mixed performances in major U.S. stock indexes, volatile oil prices due to Middle East tensions, and ongoing inflation concerns, investors are keenly observing the shifts in market dynamics. In this environment of uncertainty and fluctuating indices, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities within sectors like consumer staples and energy that have shown resilience amidst volatility.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| XTC New Energy Materials(Xiamen)Ltd (SHSE:688778) | CN¥38.00 | CN¥75.70 | 49.8% |
| Xiamen King Long Motor Group (SHSE:600686) | CN¥9.41 | CN¥18.67 | 49.6% |
| Valmet Oyj (HLSE:VALMT) | €26.78 | €53.49 | 49.9% |
| PORR (WBAG:POS) | €30.65 | €60.91 | 49.7% |
| PAL GROUP Holdings (TSE:2726) | ¥1452.00 | ¥2892.76 | 49.8% |
| Orthex Oyj (HLSE:ORTHEX) | €4.47 | €8.90 | 49.8% |
| Kumagai GumiLtd (TSE:1861) | ¥1212.00 | ¥2393.63 | 49.4% |
| Kingnet Network (SZSE:002517) | CN¥15.42 | CN¥30.52 | 49.5% |
| Inner Mongolia ERDOS ResourcesLtd (SHSE:600295) | CN¥14.28 | CN¥28.17 | 49.3% |
| Eni (BIT:ENI) | €25.775 | €51.40 | 49.9% |
Let's dive into some prime choices out of the screener.
Terumo (TSE:4543)
Overview: Terumo Corporation is a global company involved in the manufacture and sale of medical products and equipment, with operations spanning Japan, Europe, China, the United States, Asia, and other international markets; it has a market cap of approximately ¥3.40 trillion.
Operations: Terumo's revenue is primarily derived from its Cardiac and Vascular Company segment at ¥706.74 billion, followed by the Blood and Cell Technologies Company at ¥240.17 billion, and the Medical Care Solutions Company at ¥222.32 billion.
Estimated Discount To Fair Value: 24.7%
Terumo Corporation is trading at 24.7% below its estimated fair value and below future cash flow value by over 20%, indicating potential undervaluation based on cash flows. Despite recent challenges, including the termination of a supply agreement with CSL Plasma leading to significant impairment losses of approximately US$610 million, Terumo's earnings are forecast to grow at 11.37% annually, outpacing the Japanese market average growth rate.
- The growth report we've compiled suggests that Terumo's future prospects could be on the up.
- Delve into the full analysis health report here for a deeper understanding of Terumo.
Central Automotive Products (TSE:8117)
Overview: Central Automotive Products Ltd. is involved in the development, import and export, and sale of automotive parts and related services, with a market cap of ¥111.19 billion.
Operations: Central Automotive Products Ltd. generates revenue through the development, import and export, and sale of automotive parts and associated services.
Estimated Discount To Fair Value: 47%
Central Automotive Products is trading at 47% below its estimated fair value, with a significant gap between its current price (¥2,069) and future cash flow value (¥3,900.46). Despite slower forecasted earnings growth of 3.2% per year compared to the Japanese market's 9.5%, the company maintains a reliable dividend yield of 3.04%. Recent announcements include a share buyback program worth ¥2,500 million and an increase in second-quarter dividends to ¥30 per share from ¥26 last year.
- Our earnings growth report unveils the potential for significant increases in Central Automotive Products' future results.
- Click here to discover the nuances of Central Automotive Products with our detailed financial health report.
Acom (TSE:8572)
Overview: Acom Co., Ltd. operates in the financial services sector across Japan, Thailand, and internationally with a market cap of ¥707.64 billion.
Operations: The company's revenue segments consist of the Loan & Credit Card Business at ¥184.82 billion, Guarantee Business at ¥82.47 billion, Overseas Financial Business at ¥69.17 billion, and Loan Servicing Business at ¥7.50 billion.
Estimated Discount To Fair Value: 36.3%
Acom is trading at 36.3% below its estimated fair value, with its current price (¥457.6) significantly under the future cash flow value (¥718.81). Despite a modest earnings growth forecast of 3.7% annually, which lags behind the Japanese market average of 9.5%, Acom's recent ¥20 billion fixed-income offering and corrected earnings guidance underscore financial adjustments amidst slower revenue growth projections of 4.5% per year compared to the market's 6.6%.
- The analysis detailed in our Acom growth report hints at robust future financial performance.
- Take a closer look at Acom's balance sheet health here in our report.
Taking Advantage
- Investigate our full lineup of 260 Undervalued Global Stocks Based On Cash Flows right here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com